Liss' Lowdown

Liss' Lowdown

Liss' Lowdown Ep2

Preclinical Breakthrough of the week:

Drug candidate for Fatty Liver Disease shows promise in preclinical studies at the 密西根大学 ????

A recently developed glycine-based tripeptide (DT-109) was designed by researchers at the University of Michigan to treat the severe form of fatty liver disease called nonalcoholic steatohepatitis (NASH). The disease causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.

Results reveal that DT-109 reversed fat build-up and prevented scarring in the livers of both mice and primates that had developed NASH. Which is particularly promising as scientists have been trying to develop a treatment NASH for years, but many attempts have failed to show an improvement. Next stop - Clinical trials!


Clinical Breakthrough of the week:

BeVinced launches MedTech CRO services ???

BeVinced, a new leading CRO, set up by Joris Bannenberg MD PhD and Dirk Meijer MD MSc PhD specialises in Medical Device Regulation (MDR) compliance services.

The company is aimed at addressing the unique needs of the medical device industry. Services include, but are not limited to, clinical trial design and management, regulatory strategy and submissions, post-market surveillance, vigilance, CER-writing and technical documentation support as well as Legal Representative services.


Partnership of the week:

Limerston Capital has acquired Concept Life Sciences ??????????????

Since 2020, the UK-based CRO, Concept Life Sciences has made considerable investments in expanding its capacities. They have built top-notch biology facilities in Oncology and Immunology, offering unrivalled insights into quickly expanding speciality therapeutic fields and fostering innovation. Around 300 renowned scientists and more than 100 PhDs now make up its staff.?

The organisation will be able to use the additional commercial and technical flexibility coming from Limerston Captial's backing, to establish and expand its services to a new and existing customer base thanks to a new growth plan under the direction of new chief executive Ben Cliff .

#lisslowdown #cronews #cro #contractresearch #contractresearchorganization

要查看或添加评论,请登录

Elissa Buxton的更多文章

  • The 'Lowdown' on C-suite appointments in 2024

    The 'Lowdown' on C-suite appointments in 2024

    Chief Executive Officers (CEOs) Tom Zoda – CEO, Cognitive Research Corporation Tom brings nearly 30 years of experience…

  • Liss' Lowdown #32

    Liss' Lowdown #32

    Preclinical Breakthrough of the month: New Plant-Derived Compound Shows Promise Against Drug-Resistant Tuberculosis in…

  • Liss' Lowdown #31

    Liss' Lowdown #31

    Preclinical Breakthrough of the month: Neuroactive Drugs Show Promise in Preclinical Glioblastoma Treatment A recent…

  • Liss' Lowdown #30

    Liss' Lowdown #30

    Preclinical Breakthrough of the month: Lab-Grown Intestines Reveal Two Subtypes of Crohn's Disease, Paving the Way for…

    1 条评论
  • Liss' Lowdown #29

    Liss' Lowdown #29

    Preclinical Breakthrough of the month: Plasma Tau Test Shows Promise for Early Alzheimer's Detection A study presented…

    1 条评论
  • Liss' Lowdown #28

    Liss' Lowdown #28

    Preclinical Breakthrough of the month: New Treatment Approach Shows Promise Against Hard-to-Treat Breast Cancer…

  • Liss' Lowdown #27

    Liss' Lowdown #27

    Preclinical Breakthrough of the month: Gene-Editing Therapy Targets Lung Cells in Cystic Fibrosis Study A recent…

  • Liss' Lowdown #26 - 1000 Subscribers!

    Liss' Lowdown #26 - 1000 Subscribers!

    Preclinical Breakthrough of the month: Breakthrough in Herpes Cure: Gene Therapy Shows 90% Reduction in Preclinical…

    5 条评论
  • Liss' Lowdown #25

    Liss' Lowdown #25

    Preclinical Breakthrough of the month: MIRA Pharmaceuticals Advances Ketamir-2 for Mental Health and Pain Relief MIRA…

  • Liss' Lowdown #24

    Liss' Lowdown #24

    Preclinical Breakthrough of the month: Capsida Biotherapeutics Advances Next-Generation Gene Therapy for Parkinson’s…

    2 条评论

社区洞察

其他会员也浏览了